| Report | Options implied | Actual move | Market was |
|---|---|---|---|
| February 3, 2026 | ±2.4% | +1.5% | over-priced |
| November 3, 2025 | ±2.3% | -3.0% | under-priced |
| May 5, 2025 | ±2.6% | -0.5% | over-priced |
| February 3, 2025 | ±2.2% | +0.7% | over-priced |
| October 30, 2024 | ±1.2% | -0.2% | over-priced |
| April 30, 2024 | ±1.6% | -0.7% | over-priced |
| February 1, 2024 | ±1.9% | +1.9% | under-priced |
| November 1, 2023 | ±2.4% | -2.0% | over-priced |
| Quarter | EPS (dil.) | Revenue | Net income |
|---|---|---|---|
| Q2 FY2026 | $1.29 | $1.7B | $161M |
| Q1 FY2026 | $0.65 | $1.4B | $82M |
| Q4 FY2025 | $2.68 | $2.0B | $336M |
| Q3 FY2025 | $1.50 | $1.7B | $191M |
Clorox Company (CLX) reports in 5 days, with the next report estimated for August 2, 2026. Across the last 8 reports, options priced an average ±2.1% earnings move while the stock actually moved 1.3% on average — the market has systematically over-priced CLX's earnings risk. Fundamentals into the print: EPS down 16.2% year-over-year, revenue down 0.8%. QuantLogix's live 5-factor engine currently reads CLX as a strong buy at 70/100.
Implied move is derived from at-the-money option pricing; actual moves are close-to-close on report days. Next-report dates are estimates until confirmed by the company. Educational market analysis, not investment advice. Browse all signal scorecards →